PMID- 28430159
OWN - NLM
STAT- MEDLINE
DCOM- 20180216
LR  - 20240109
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 15
IP  - 4
DP  - 2017 Apr 21
TI  - Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic 
      Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial.
LID - 10.3390/md15040122 [doi]
LID - 122
AB  - BACKGROUND: Low-molecular-weight fucoidan (LMF) is widely used as a food 
      supplement for cancer patients. However, all of the studies are in vitro or were 
      conducted using mice. Therefore, powerful clinical evidence for LMF use is 
      relatively weak. This study aimed to evaluate the efficacy of LMF as a 
      supplemental therapy to chemo-target agents in metastatic colorectal cancer 
      (mCRC) patients. METHODS: We conducted a prospective, randomized, double-blind, 
      controlled trial to evaluate the efficacy of LMF as a supplemental therapy to 
      chemotarget agents in patients with metastatic colorectal cancer (mCRC). Sixty 
      eligible patients with mCRC were included. Finally, 54 patients were enrolled, of 
      whom 28 were included in the study group and 26 in the control group. The primary 
      endpoint was the disease control rate (DCR), and secondary endpoints included the 
      overall response rate (ORR), progression-free survival (PFS), overall survival 
      (OS), adverse effects (AEs), and quality of life (QOL). RESULTS: The DCRs were 
      92.8% and 69.2% in the study and control groups, respectively (p = 0.026), in a 
      median follow-up period of 11.5 months. The OS, PFS, ORR, AEs, and QOL did not 
      significantly differ between the two groups. CONCLUSION: This is the first 
      clinical trial evaluating the efficacy of LMF as a supplemental therapy in the 
      management of patients with mCRC. The results indicate that LMF combined with 
      chemotarget agents significantly improved the DCR.
FAU - Tsai, Hsiang-Lin
AU  - Tsai HL
AD  - Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical 
      University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 
      chunpin870132@yahoo.com.tw.
AD  - Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung 
      Medical University, Kaohsiung 807, Taiwan. chunpin870132@yahoo.com.tw.
FAU - Tai, Chi-Jung
AU  - Tai CJ
AD  - Graduate Institute of Natural Product, College of Pharmacy, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. taichijung@gmail.com.
AD  - Department of Family Medicine, Pingtung Hospital, Ministry of Health and Welfare, 
      Pingtung 928, Taiwan. taichijung@gmail.com.
FAU - Huang, Ching-Wen
AU  - Huang CW
AD  - Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical 
      University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 
      baseball5824@yahoo.com.tw.
AD  - Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung 
      Medical University, Kaohsiung 807, Taiwan. baseball5824@yahoo.com.tw.
FAU - Chang, Fang-Rong
AU  - Chang FR
AD  - Graduate Institute of Natural Product, College of Pharmacy, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. aaronfrc@kmu.edu.tw.
FAU - Wang, Jaw-Yuan
AU  - Wang JY
AD  - Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical 
      University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 
      jawyuanwang@gmail.com.
AD  - Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung 
      Medical University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com.
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com.
AD  - Center for Biomarkers and Biotech Drugs, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com.
AD  - Research Center for Environmental Medicine, College of Medicine, Kaohsiung 
      Medical University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com.
AD  - Research Center for Natural Products & Drug Development, Kaohsiung Medical 
      University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170421
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Polysaccharides)
RN  - 9072-19-9 (fucoidan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Dietary Supplements
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polysaccharides/*therapeutic use
MH  - Prospective Studies
MH  - Quality of Life
PMC - PMC5408268
OTO - NOTNLM
OT  - disease control rate
OT  - low-molecular-weight fucoidan
OT  - metastatic colorectal cancer
OT  - supplemental therapy
COIS- The authors declare no conflict of interest.
EDAT- 2017/04/22 06:00
MHDA- 2018/02/17 06:00
PMCR- 2017/04/01
CRDT- 2017/04/22 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/04/12 00:00 [revised]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/04/22 06:00 [entrez]
PHST- 2017/04/22 06:00 [pubmed]
PHST- 2018/02/17 06:00 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - md15040122 [pii]
AID - marinedrugs-15-00122 [pii]
AID - 10.3390/md15040122 [doi]
PST - epublish
SO  - Mar Drugs. 2017 Apr 21;15(4):122. doi: 10.3390/md15040122.